ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
University of Milan at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
University of Milan takes part in 12 sessions at ESMO 2026 in Madrid. Its program spans breast cancer, blood cancers, lung cancer, and rare tumours, with attention to cancer care under resource constraints. Specific topics include treatment options for advanced breast cancer and prognostic assessment in myelofibrosis.
| Organization | ESMO 2026 Attendance |
|---|---|
University of Milan Milan, Italy | |
Public research university in Milan, Italy, with a faculty of medicine and surgery. | Poster Fri Oct 23 13:00–15:00 Diagnostic management of cardiac masses and primary cardiac sarcoma (PCS): A nationwide Italian survey Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 14:20–14:35 Pharmacology perspective Breast cancer Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Chair Sat Oct 24 16:30–18:00 Updates on myeloid neoplasms with a focus on medical oncology practice Haematological malignancies Talk Sat Oct 24 17:30–17:50 Prognostic assessment to guide treatment of myelofibrosis Haematological malignancies Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Chair Sun Oct 25 14:45–16:15 Talk Sun Oct 25 15:30–15:45 Chair Mon Oct 26 10:15–11:45 Talk Mon Oct 26 11:22–11:37 Poster Mon Oct 26 12:00–12:45 Clinical outcomes and molecular landscape of metastatic extrapulmonary neuroendocrine carcinomas (mEP-NEC) beyond first-line failure Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Satellite Mon Oct 26 18:45–19:00 Mechanism of action and differentiating characteristics of immune checkpoint inhibitors Lung & thoracic cancers |
Find decision makers at University of Milan
Tell us what you sell and we’ll find the people at University of Milan most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction